Diep Nguyen Bich, Trang Nguyen Thu, Huy Do Duc, Van Hoang Thi Hai, Truc Thai Thanh, Van Dung Do, Li Michael J, Shoptaw Steve J, Li Li, Giang Le Minh
Center for Training and Research on Substance Use & HIV, Hanoi Medical University, Hanoi, Viet Nam.
University of Medicine and Pharmacy at Ho Chi Minh City, Viet Nam.
J Subst Use Addict Treat. 2025 Jun;173:209686. doi: 10.1016/j.josat.2025.209686. Epub 2025 Mar 27.
The global rise of concurrent use of opioids and methamphetamine presents challenges to stable methadone maintenance treatment (MMT). We assessed non-adherence to treatment and concurrent opioid use, along with associated factors, among people on MMT using methamphetamine in Vietnam.
This analysis utilized baseline data from a randomized clinical trial designed to investigate the effectiveness of various combinations of behavioral evidence-based interventions for methamphetamine use among patients on MMT in Vietnam (STAR-OM R01DA050486). We used data from 498 participants on MMT who self-reported using methamphetamine in the past 30 days and had been in MMT treatment for at least three months. The study determined adherence to MMT through medical record review and assessed concurrent opioid use via urine testing and documented test results in medical records.
Within the last three months, 145 (29.1 %) did not adhere to MMT, and 212 (42.6 %) concurrently used opioids. Non-adherence to MMT were strongly associated with living at a considerable distance from the clinic (aOR = 1.80, 95 % CI: 1.10-2.90), being HIV positive (aOR = 0.51, 95 % CI: 0.27-0.97), and were marginally associated with using methamphetamine to reduce emotional distress (aOR = 1.56, 95 % CI: 0.99-2.45). Concurrent opioid use was associated with receiving treatment at clinics established during the scale-up period (aOR = 1.80, 95 % CI: 1.13-2.87), an extended duration of treatment at current clinics (aOR = 0.98, 95 % CI: 0.97-0.99), male gender (aOR = 2.09, 95 % CI: 1.05-4.13), and ever injecting methamphetamine (aOR = 1.98, 95 % CI: 1.13-3.46), besides MMT non-adherence (aOR = 2.71, 95 % CI: 1.72-4.29).
Non-adherence to MMT and concurrent opioid use are prevalent among methamphetamine-using patients on methadone in Vietnam. Alongside well-documented factors influencing methadone program, the rise in methamphetamine adds further complexity to these challenges. Future intervention strategies must address both the underlying issues and methamphetamine use behaviors to effectively improve treatment outcomes.
NCT04706624. Registered 13 January 2021. https://clinicaltrials.gov/ct2/show/NCT04706624.
阿片类药物与甲基苯丙胺同时使用的情况在全球范围内呈上升趋势,这给美沙酮维持治疗(MMT)的稳定性带来了挑战。我们评估了越南接受MMT治疗且使用甲基苯丙胺的人群中治疗不依从情况、同时使用阿片类药物的情况及其相关因素。
本分析利用了一项随机临床试验的基线数据,该试验旨在研究越南接受MMT治疗的患者中基于行为的循证干预措施的各种组合对甲基苯丙胺使用的有效性(STAR-OM R01DA050486)。我们使用了498名接受MMT治疗的参与者的数据,这些参与者在过去30天内自我报告使用过甲基苯丙胺,且接受MMT治疗至少三个月。该研究通过病历审查确定MMT治疗的依从性,并通过尿液检测评估同时使用阿片类药物的情况,并将检测结果记录在病历中。
在过去三个月内,145人(29.1%)未坚持MMT治疗,212人(42.6%)同时使用阿片类药物。MMT治疗不依从与居住地距诊所较远(调整后的比值比[aOR]=1.80,95%置信区间[CI]:1.10-2.90)、HIV阳性(aOR=0.51,95%CI:0.27-0.97)密切相关,与使用甲基苯丙胺减轻情绪困扰有微弱关联(aOR=1.56,95%CI:0.99-2.45)。同时使用阿片类药物与在扩大治疗阶段设立的诊所接受治疗(aOR=1.80,95%CI:1.13-2.87)、在当前诊所的治疗时间延长(aOR=0.98,95%CI:0.97-0.99)、男性(aOR=2.09,95%CI:1.05-4.13)以及曾注射甲基苯丙胺(aOR=1.98,95%CI:1.13-3.46)有关,此外还与MMT治疗不依从有关(aOR=2.71,95%CI:1.72-4.29)。
在越南接受美沙酮治疗且使用甲基苯丙胺的患者中,MMT治疗不依从和同时使用阿片类药物的情况很普遍。除了影响美沙酮项目的诸多已充分记录的因素外,甲基苯丙胺使用情况的增加使这些挑战更加复杂。未来的干预策略必须解决潜在问题和甲基苯丙胺使用行为,以有效改善治疗效果。
NCT04706624。于2021年1月13日注册。https://clinicaltrials.gov/ct2/show/NCT04706624 。